{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:08:51Z","timestamp":1789675731194,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07641-0","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:24:17Z","timestamp":1762835057000},"page":"2455-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Histopathologic analysis of intrahepatic cholangiocarcinoma treated with transarterial radioembolization using Yttrium-90 resin microspheres"],"prefix":"10.1007","volume":"53","author":[{"given":"Muhammad Mohid","family":"Tahir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad A.","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Odeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamir","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja N.","family":"De Paepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charissa","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safija","family":"Nizamic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha S.","family":"Shenoy-Bhangle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bullock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Eckhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-9881","authenticated-orcid":false,"given":"Ammar","family":"Sarwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"7641_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-04966-4","volume":"43","author":"L Wu","year":"2019","unstructured":"Wu L, Tsilimigras DI, Paredes AZ, Mehta R, Hyer JM, Merath K, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World J Surg. 2019;43:1. https:\/\/doi.org\/10.1007\/s00268-019-04966-4.","journal-title":"World J Surg"},{"key":"7641_CR2","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejso.2020.01.028","volume":"46","author":"N Machairas","year":"2020","unstructured":"Machairas N, Lang H, Jayant K, Raptis DA, Sotiropoulos GC. Intrahepatic cholangiocarcinoma: limitations for resectability, current surgical concepts and future perspectives. Eur J Surg Oncol. 2020;46:740\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2020.01.028.","journal-title":"Eur J Surg Oncol"},{"key":"7641_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1245\/s10434-007-9627-x","volume":"15","author":"JCC Tan","year":"2008","unstructured":"Tan JCC, Coburn NG, Baxter NN, Kiss A, Law CHL. Surgical management of intrahepatic cholangiocarcinoma - a population-based study. Ann Surg Oncol. 2008;15:600\u20138. https:\/\/doi.org\/10.1245\/s10434-007-9627-x.","journal-title":"Ann Surg Oncol"},{"key":"7641_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1245\/s10434-012-2312-8","volume":"20","author":"A Kato","year":"2013","unstructured":"Kato A, Shimizu H, Ohtsuka M, Yoshidome H, Yoshitomi H, Furukawa K, et al. Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study. Ann Surg Oncol. 2013;20:318\u201324. https:\/\/doi.org\/10.1245\/s10434-012-2312-8.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"7641_CR5","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1007\/s00268-018-4558-1","volume":"42","author":"T Sumiyoshi","year":"2018","unstructured":"Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 2018;42(9):2910\u20138. https:\/\/doi.org\/10.1007\/s00268-018-4558-1.","journal-title":"World J Surg"},{"key":"7641_CR6","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, Verdure L, Sulpice L, Bourien H, et al. Downstaging with radioembolization or chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2020;27:3729\u201337. https:\/\/doi.org\/10.1245\/s10434-020-08486-7.","journal-title":"Ann Surg Oncol"},{"key":"7641_CR7","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.jvir.2021.08.009","volume":"32","author":"A Sarwar","year":"2021","unstructured":"Sarwar A, Ali A, Ljuboja D, Weinstein JL, Shenoy-Bhangle AS, Nasser IA, et al. Neoadjuvant Yttrium-90 transarterial radioembolization with resin microspheres prescribed using the medical internal radiation dose model for intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2021;32:1560\u20138. https:\/\/doi.org\/10.1016\/j.jvir.2021.08.009.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/sla.0000000000001384","volume":"262","author":"VG Agopian","year":"2015","unstructured":"Agopian VG, Morshedi MM, McWilliams J, Harlander-Locke MP, Markovic D, Zarrinpar A, et al. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation. Ann Surg. 2015;262:536\u201345. https:\/\/doi.org\/10.1097\/sla.0000000000001384.","journal-title":"Ann Surg"},{"key":"7641_CR9","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.hpb.2023.01.011","volume":"25","author":"RI Ayabe","year":"2023","unstructured":"Ayabe RI, Paez-Arango N, Estrella JS, Newhook TE, Tzeng C-WD, Chun YS, et al. Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma \u2013 does pathologic response mean better outcomes? HPB. 2023;25:472\u201380. https:\/\/doi.org\/10.1016\/j.hpb.2023.01.011.","journal-title":"HPB"},{"key":"7641_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40792-024-01832-x","volume":"10","author":"Y Shimamaki","year":"2024","unstructured":"Shimamaki Y, Hosokawa I, Takayashiki T, Takano S, Sonoda I, Ohtsuka M. Pathological complete response following neoadjuvant chemotherapy for locally advanced intrahepatic cholangiocarcinoma. Surg Case Rep. 2024;10:35. https:\/\/doi.org\/10.1186\/s40792-024-01832-x.","journal-title":"Surg Case Rep"},{"issue":"Suppl 3","key":"7641_CR11","doi-asserted-by":"publisher","first-page":"S1093","DOI":"10.1245\/s10434-015-4768-9","volume":"22","author":"A Kato","year":"2015","unstructured":"Kato A, Shimizu H, Ohtsuka M, Yoshitomi H, Furukawa K, Takayashiki T, et al. Downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer patients treated with gemcitabine plus cisplatin combination therapy followed by radical surgery. Ann Surg Oncol. 2015;22(Suppl 3):S1093\u20139. https:\/\/doi.org\/10.1245\/s10434-015-4768-9.","journal-title":"Ann Surg Oncol"},{"key":"7641_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-5-36","volume":"5","author":"MW Slupski","year":"2007","unstructured":"Slupski MW, Szczylik C, Jasinski MK. Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma. World J Surg Oncol. 2007;5:36. https:\/\/doi.org\/10.1186\/1477-7819-5-36.","journal-title":"World J Surg Oncol"},{"key":"7641_CR13","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1007\/s10620-015-3640-x","volume":"60","author":"TB Tran","year":"2015","unstructured":"Tran TB, Bal CK, Schaberg K, Longacre TA, Chatrath BS, Poultsides GA. Locally advanced intrahepatic cholangiocarcinoma: complete pathologic response to neoadjuvant chemotherapy followed by left hepatic trisectionectomy and caudate lobectomy. Dig Dis Sci. 2015;60:3226\u20139. https:\/\/doi.org\/10.1007\/s10620-015-3640-x.","journal-title":"Dig Dis Sci"},{"key":"7641_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s13691-018-0327-0","volume":"7","author":"T Tatsuguchi","year":"2018","unstructured":"Tatsuguchi T, Gotoh K, Kobayashi S, Asukai K, Tomokuni A, Akita H, et al. Pathologic complete response after gemcitabine and S-1 chemotherapy for far advanced intrahepatic cholangiocarcinoma. Int Cancer Conf J. 2018;7:93\u20137. https:\/\/doi.org\/10.1007\/s13691-018-0327-0.","journal-title":"Int Cancer Conf J"},{"key":"7641_CR15","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3892\/mco.2016.1065","volume":"5","author":"T Matsubara","year":"2016","unstructured":"Matsubara T, Nishida T, Tomimaru Y, Yamamoto M, Hayashi S, Nakajima S, et al. Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine\/cisplatin\/S-1 combination chemotherapy: a case report. Mol Clin Oncol. 2016;5:757\u201361. https:\/\/doi.org\/10.3892\/mco.2016.1065.","journal-title":"Mol Clin Oncol"},{"key":"7641_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s12328-022-01700-x","volume":"15","author":"T Sumiyoshi","year":"2022","unstructured":"Sumiyoshi T, Uemura K, Shintakuya R, Okada K, Otsuka H, Serikawa M, et al. A case of unresectable locally advanced intrahepatic cholangiocarcinoma that achieved pathological complete response after gemcitabine and S1 chemotherapy. Clin J Gastroenterol. 2022;15:1164\u20138. https:\/\/doi.org\/10.1007\/s12328-022-01700-x.","journal-title":"Clin J Gastroenterol"},{"key":"7641_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051130","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Tang H, Fan J, Wang R, Han Y, Su S, et al. Case report: a report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy. Front Immunol. 2022;13:1051130. https:\/\/doi.org\/10.3389\/fimmu.2022.1051130.","journal-title":"Front Immunol"},{"key":"7641_CR18","doi-asserted-by":"publisher","unstructured":"Abudalou M, Vega EA, Kondratiev S, Conrad C, Kozyreva O. Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus.13:e20187. https:\/\/doi.org\/10.7759\/cureus.20187","DOI":"10.7759\/cureus.20187"},{"key":"7641_CR19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s00270-022-03183-2","volume":"45","author":"AN Gupta","year":"2022","unstructured":"Gupta AN, Gordon AC, Gabr A, Kalyan A, Kircher SM, Mahalingam D, et al. Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort. Cardiovasc Intervent Radiol. 2022;45:1117\u201328. https:\/\/doi.org\/10.1007\/s00270-022-03183-2.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"7641_CR20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jvir.2022.12.017","volume":"34","author":"O Ahmed","year":"2023","unstructured":"Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao C-y, et al. Yttrium-90 radioembolization and concomitant systemic gemcitabine, cisplatin, and capecitabine as the first-line therapy for locally advanced intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2023;34:702\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2022.12.017.","journal-title":"J Vasc Interv Radiol"},{"issue":"20","key":"7641_CR21","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.18632\/oncotarget.28060","volume":"12","author":"R Paz-Fumagalli","year":"2021","unstructured":"Paz-Fumagalli R, Core J, Padula C, Montazeri S, McKinney J, Frey G, et al. Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma. Oncotarget. 2021;12(20):2075\u201388. https:\/\/doi.org\/10.18632\/oncotarget.28060.","journal-title":"Oncotarget"},{"key":"7641_CR22","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1016\/j.jvir.2023.07.028","volume":"34","author":"Q Yu","year":"2023","unstructured":"Yu Q, Patel M, Kwak D, Ungchusri E, Wang Y, Van Ha T, et al. Segmental Yttrium-90 radioembolization using glass microspheres greater than 400 Gray for the treatment of intrahepatic cholangiocarcinoma: A preliminary experience. J Vasc Interv Radiol. 2023;34:1970. 6.e1.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR23","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jss.2009.05.021","volume":"166","author":"R Whitney","year":"2011","unstructured":"Whitney R, Tatum C, Hahl M, Ellis S, Scoggins CR, McMasters K, et al. Safety of hepatic resection in metastatic disease to the liver after Yttrium-90 therapy. J Surg Res. 2011;166:236\u201340. https:\/\/doi.org\/10.1016\/j.jss.2009.05.021.","journal-title":"J Surg Res"},{"key":"7641_CR24","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/jso.24967","volume":"117","author":"C Justinger","year":"2018","unstructured":"Justinger C, Gruden J, Kouladouros K, Stravodimos C, Reimer P, Tannapfel A, et al. Histopathological changes resulting from selective internal radiotherapy (SIRT). J Surg Oncol. 2018;117:1084\u201391. https:\/\/doi.org\/10.1002\/jso.24967.","journal-title":"J Surg Oncol"},{"key":"7641_CR25","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","volume":"60","author":"AS Kennedy","year":"2004","unstructured":"Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552\u201363. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.09.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7641_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.humpath.2008.06.024","volume":"40","author":"MA Nalesnik","year":"2009","unstructured":"Nalesnik MA, Federle M, Buck D, Fontes P, Carr BI. Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. Hum Pathol. 2009;40:125\u201334. https:\/\/doi.org\/10.1016\/j.humpath.2008.06.024.","journal-title":"Hum Pathol"},{"key":"7641_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatology"},{"key":"7641_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.jvir.2018.06.027","volume":"29","author":"A Gabr","year":"2018","unstructured":"Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29:1502. 10.e1.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR29","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1007\/s00259-022-05776-y","volume":"49","author":"SA Montazeri","year":"2022","unstructured":"Montazeri SA, De la Garza-Ramos C, Lewis AR, Lewis JT, LeGout JD, Sella DM, et al. Hepatocellular carcinoma radiation segmentectomy treatment intensification prior to liver transplantation increases rates of complete pathologic necrosis: an explant analysis of 75 tumors. Eur J Nucl Med Mol Imaging. 2022;49:3892\u20137. https:\/\/doi.org\/10.1007\/s00259-022-05776-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7641_CR30","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of Solitary, unresectable HCC: the LEGACY study. Hepatology. 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatology"},{"key":"7641_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"7641_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.jvir.2013.10.056","volume":"25","author":"JC Camacho","year":"2014","unstructured":"Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European association for the study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25:256\u201365. https:\/\/doi.org\/10.1016\/j.jvir.2013.10.056.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207\u201314. https:\/\/doi.org\/10.1002\/1097-0142(19810101)47:1%3C207::aid-cncr2820470134%3E3.0.co;2-6.","journal-title":"Cancer"},{"key":"7641_CR34","unstructured":"CTCAE and, Reporting - AE. NCI. 2025."},{"key":"7641_CR35","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1002\/hep.22747","volume":"49","author":"A Riaz","year":"2009","unstructured":"Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic\u2013pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres #. Hepatology. 2009;49:1185\u201393. https:\/\/doi.org\/10.1002\/hep.22747.","journal-title":"Hepatology"},{"key":"7641_CR36","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","volume":"32","author":"B Toskich","year":"2021","unstructured":"Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, et al. Pathologic response of hepatocellular carcinoma treated with Yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: A validation study. J Vasc Interv Radiol. 2021;32:518\u2013e261. https:\/\/doi.org\/10.1016\/j.jvir.2020.12.019.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR37","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jvir.2023.05.026","volume":"34","author":"B Kis","year":"2023","unstructured":"Kis B, Shridhar R, Mhaskar R, Gyano M, Frakes JM, El-Haddad G, et al. Radioembolization with Yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma-a prospective feasibility study. J Vasc Interv Radiol. 2023;34:1547\u201355. https:\/\/doi.org\/10.1016\/j.jvir.2023.05.026.","journal-title":"J Vasc Interv Radiol"},{"key":"7641_CR38","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","volume":"43","author":"I Bargellini","year":"2020","unstructured":"Bargellini I, Mosconi C, Pizzi G, Lorenzoni G, Vivaldi C, Cappelli A, et al. Yttrium-90 radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study. Cardiovasc Intervent Radiol. 2020;43:1305\u201314. https:\/\/doi.org\/10.1007\/s00270-020-02569-4.","journal-title":"Cardiovasc Intervent Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07641-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07641-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T05:38:32Z","timestamp":1771479512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07641-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7641"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07641-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Dana-Farber\/Harvard Cancer Center (IRB# 20\u2013355).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was waived because of the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"A.S. Grants or contracts from Sirtex Medical, consulting fees from ABK Biomedical and Boston Scientific, participation on a medical advisory board for Sirtex Medical and Boston Scientific, chair of economics for the Society of Interventional Radiology. A.B. advisory fees from Sirtex. M.A. consulting fees form Sirtex Medical and served on a medical advisory board for Boston Scientific. M.M.T, I.N., M.O., A.A., K.D.P., C.K., S.N., D.D., J.L.W., A.S.B., M.D., and D.E. declare they have no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}